Newsroom
Strive to Deliver Breakthroughs
-
April 06, 2022
Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 6, 2022 Harbour BioMed (“HBM”, HKEX: 02142), a global biopharmaceutical company ...
View more -
March 25, 2022
Harbour BioMed Reports Full Year 2021 Financial Results: Two Late-stage Programs Are Accelerating Towards Commercialization with Robust Innovation and Globalization Capabilities
CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - March 25, 2022 Harbour BioMed (“HBM” or the “Company”; HKEX: 021...
View more -
February 28, 2022
Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia
Cambridge, MA, Rotterdam, NL, Suzhou, CN— February 28, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has been appr...
View more -
February 21, 2022
Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody in Asthma
Cambridge, MA, Rotterdam, NL, Suzhou, CN - February 21, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Me...
View more -
January 24, 2022
Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 24, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successful...
View more -
January 13, 2022
Harbour BioMed Completes the First Interim Analysis of Phase III Clinical Trial of Tanfanercept
Cambridge, MA, Rotterdam, NL, Suzhou, CN — January 13, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, the Company has ...
View more -
January 04, 2022
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
Cambridge, MA, Rotterdam, NL, Suzhou, CN — January 4, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, its next generati...
View more -
October 19, 2021
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease
Cambridge, MA, Rotterdam, NL, Suzhou, CN— October 19, 2021 Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical...
View more -
September 27, 2021
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis
Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 27, 2021 Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical tr...
View more -
September 14, 2021
Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003
Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 14, 2021 Harbour BioMed (“HBM”, HKEX: 02142) announced that the China Nation...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1